Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow
Caroline J. Breitbach(University of Ottawa), John C. Bell(Ottawa Hospital), Harold Atkins(University of Ottawa), Jennifer M Paterson(University of Ottawa), J. Andrea McCart(Toronto General Hospital), Manijeh Daneshmand(University of Ottawa), Chantal G. Lemay(University of Ottawa), Kelly Speth, David F. Stojdl(Ottawa Regional Cancer Foundation), David H. Kirn(Alameda Applied Sciences Corporation (United States)), Theresa Falls(Ottawa Hospital), Kelley A. Parato, Allison McGuire(University of Ottawa)
Cited by 277
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419